CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients.
Fiche du document
- doi: 10.1016/j.atherosclerosis.2021.09.019
- issn: 0021-9150
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.atherosclerosis.2021.09.019
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34597881
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1879-1484
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3343771B7BD57
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Heart--Infarction Myocardial infarct Myocardium--Infarction Heart attack MI (Myocardial infarction) Heart infarctionCiter ce document
T. Mahendiran et al., « CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. », Serveur académique Lausannois, ID : 10.1016/j.atherosclerosis.2021.09.019
Métriques
Partage / Export
Résumé
CCN family member 1 (CCN1) has recently been proposed as a novel biomarker of myocardial injury, improving prediction of 30-day and one-year mortality following acute coronary syndromes. Among ST-elevation myocardial infarction (STEMI) patients, we evaluated the utility of CCN1 measured immediately before primary percutaneous coronary intervention (PPCI) as a predictor of two earlier endpoints: final myocardial infarct size and post-infarction left ventricular ejection fraction (LVEF). Furthermore, we evaluated the impact of CCN1 on the discriminatory power of the CADILLAC score. STEMI patients were obtained from the SPUM-ACS cohort. Serum CCN1 was measured prior to PPCI. Linear regression assessed the association between CCN1, peak creatinine kinase (CK), and post-infarction LVEF. Cox models assessed an association between CCN1 and 30-day all-cause mortality. CCN1 was measured in 989 patients with a median value of 706.2 ng/l (IQR 434.3-1319.6). A significant correlation between CCN1, myocardial infarct size (peak CK) and LVEF was observed in univariate and multivariate analysis (both p < 0.001). Even among patients with normal classical cardiac biomarker levels at the time of PPCI, CCN1 correlated significantly with final infarct size. CCN1 significantly improved prediction of 30-day all-cause mortality by the CADILLAC score (C-index 0.864, likelihood-ratio chi-square test statistic 6.331, p = 0.012; IDI 0.026, p= 0.050). Compared with classical cardiac biomarkers, CCN1 is potentially the earliest predictor of final myocardial infarct size and post-infarction LVEF. CCN1 improved the discriminatory capacity of the CADILLAC score suggesting a potential role in the very-early risk stratification of STEMI patients.